All Oncology News

Barriers in utilizing remote collection of patient-reported outcomes persist, although it has been proven to be effective in breast cancer.

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.

AI-assisted training of pathologists enhanced the accuracy of HER2 IHC scoring, potentially expanding eligibility for HER2-targeted treatments.

The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.

Olutasidenib was effective both as monotherapy and in combination with azacitidine in patients with IDH1-mutated AML arising from an MPN.

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.

Alexis LeVee, MD, discusses ongoing phase 3 trials evaluating the first-line use of ADCs in both PD-L1–positive and –negative TNBC.

Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.